

Performance in Initiating - Q4: 2016/2017 (1st April 2016 - 31st March 2017) - non HRA studies

| Research Ethics Committee Reference Number | IRAS number | Name of Trial | Date of Receipt of Valid Research Application | Date of NHS Permission | Date of First Patient Recruited | Duration between VRA and First Patient | Benchmark Met | Comments | Reasons for delay correspond to: |
|--|-------------|--|---|------------------------|---------------------------------|--|---------------|--|----------------------------------|
| 14/SC/0171 | 120104 | Add-Aspirin: A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours | 21/03/2016 | 22/04/2016 | 11/01/2017 | 296 | No | FP. Submitted early due to HRA changeover requirements | Neither |
| 15/EM/0437 | 184390 | COLUMBUS: Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration | 21/03/2016 | 05/04/2016 | 16/06/2016 | 87 | No | FP. Submitted early due to HRA changeover requirements | Neither |
| 15/NI/00243 | 191267 | EMPIRE: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis | 30/03/2016 | 08/04/2016 | | | No | FP. No patients consented yet. | Neither |
| 16/SC/0158 | 187578 | ALLIKAT: II Ligaments Left In Knee Arthroplasty Trial | 24/03/2016 | 12/07/2016 | 18/10/2016 | 208 | No | FP. Submitted early due to HRA changeover requirement | Neither |
| 15/EM/0552 | 189887 | CIRCLE: A Phase 2, randomised, double masked, sham controlled, multi centre study to evaluate the efficacy and safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment in Subjects with Non Proliferative Diabetic Retinopathy | 21/03/2016 | 14/07/2016 | 06/10/2016 | 199 | No | FP. Submitted early due to HRA changeover requirement | Neither |
| 15/NI/0177 | 167436 | IVAN follow up: ive year observational follow-up of the IVAN trial cohort: a study of function and morphology | 06/04/2016 | 20/07/2016 | 12/10/2016 | 189 | No | FP. Submitted early due to HRA changeover requirement | Neither |

| | | | | | | | | | |
|-----------------|--------|--|------------|------------|------------|-----|----|--|---------|
| 16/WM/0001 (FP) | 20668 | WHITE4: World Hip Trauma Evaluation Four: A randomised controlled trial of the sliding hip screw versus XBolt dynamic plating system for the fixation of trochanteric fractures of the hip | 21/03/2016 | 12/09/2016 | 25/10/2016 | 218 | No | FP. Submitted early due to HRA changeover requirement | Neither |
| 16/WM/0001 (WP) | 20668 | WHITE4: World Hip Trauma Evaluation Four: A randomised controlled trial of the sliding hip screw versus XBolt dynamic plating system for the fixation of trochanteric fractures of the hip | 22/03/2016 | 12/09/2016 | 05/10/2016 | 197 | No | WP. Submitted early due to HRA changeover requirement | Neither |
| 15/EE/0010 | 138590 | Pitches: Phase III trial of UDCA in ICP: V1 | 22/03/2016 | 22/03/2016 | 18/08/2016 | 149 | No | FP. Lack of communication and documents/ access for pharmacy | Both |